ATE510558T1 - Verwendung von biologisch aktivem hiv-1 tat, fragmenten oder derivaten davon, zur bestimmung und/oder aktivierung von antigen-präsentierenden zellen, und/oder zur abgabe von cargo-molekülen für impfung und/oder für behandlung von anderen erkrankungen - Google Patents

Verwendung von biologisch aktivem hiv-1 tat, fragmenten oder derivaten davon, zur bestimmung und/oder aktivierung von antigen-präsentierenden zellen, und/oder zur abgabe von cargo-molekülen für impfung und/oder für behandlung von anderen erkrankungen

Info

Publication number
ATE510558T1
ATE510558T1 AT02767265T AT02767265T ATE510558T1 AT E510558 T1 ATE510558 T1 AT E510558T1 AT 02767265 T AT02767265 T AT 02767265T AT 02767265 T AT02767265 T AT 02767265T AT E510558 T1 ATE510558 T1 AT E510558T1
Authority
AT
Austria
Prior art keywords
vaccination
tat
fragments
diseases
derivatives
Prior art date
Application number
AT02767265T
Other languages
English (en)
Inventor
Barbara Ensoli
Original Assignee
Ist Superiore Sanita
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ist Superiore Sanita filed Critical Ist Superiore Sanita
Application granted granted Critical
Publication of ATE510558T1 publication Critical patent/ATE510558T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
AT02767265T 2001-07-26 2002-07-26 Verwendung von biologisch aktivem hiv-1 tat, fragmenten oder derivaten davon, zur bestimmung und/oder aktivierung von antigen-präsentierenden zellen, und/oder zur abgabe von cargo-molekülen für impfung und/oder für behandlung von anderen erkrankungen ATE510558T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01118114A EP1279404A1 (de) 2001-07-26 2001-07-26 Verwendung von HIV-1 Fragmenten oder Derivaten zur Bestimmung oder Aktivierung von Antigen-präsentierenden Zellen, oder zur Abgabe von Cargo-Molekülen für Impfung oder für Behandlung von anderen Erkrankungen
PCT/EP2002/008377 WO2003009867A1 (en) 2001-07-26 2002-07-26 Use of biologically active hiv-1 tat, fragments or derivates thereof, to target and/or to activate antigen-presenting cells, and/or to deliver cargo molecules for preventive or therapeutic vaccination and/or to treat other diseases

Publications (1)

Publication Number Publication Date
ATE510558T1 true ATE510558T1 (de) 2011-06-15

Family

ID=8178141

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02767265T ATE510558T1 (de) 2001-07-26 2002-07-26 Verwendung von biologisch aktivem hiv-1 tat, fragmenten oder derivaten davon, zur bestimmung und/oder aktivierung von antigen-präsentierenden zellen, und/oder zur abgabe von cargo-molekülen für impfung und/oder für behandlung von anderen erkrankungen

Country Status (19)

Country Link
US (1) US7811573B2 (de)
EP (2) EP1279404A1 (de)
JP (1) JP5134183B2 (de)
CN (1) CN1318091C (de)
AP (1) AP2004002986A0 (de)
AT (1) ATE510558T1 (de)
AU (1) AU2002331350B2 (de)
BR (1) BR0211474A (de)
CA (1) CA2455227C (de)
DK (1) DK1425035T3 (de)
EA (1) EA006850B1 (de)
ES (1) ES2367255T3 (de)
HU (1) HUP0400660A2 (de)
IL (1) IL160015A0 (de)
MX (1) MXPA04000287A (de)
NZ (1) NZ531364A (de)
OA (1) OA12701A (de)
PL (1) PL368243A1 (de)
WO (1) WO2003009867A1 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0323840D0 (en) * 2003-10-10 2003-11-12 Ist Superiore Sanita Vaccines
GB0405480D0 (en) 2004-03-11 2004-04-21 Istituto Superiore Di Sanito Novel tat complexes,and vaccines comprising them
WO2005090968A1 (en) 2004-03-16 2005-09-29 Inist Inc. Tat-based immunomodulatory compositions and methods of their discovery and use
US9492400B2 (en) 2004-11-04 2016-11-15 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
CN100429228C (zh) * 2005-06-17 2008-10-29 中国人民解放军第三军医大学第三附属医院 重组人a20蛋白及其用途
US9267937B2 (en) 2005-12-15 2016-02-23 Massachusetts Institute Of Technology System for screening particles
EP2007435B1 (de) 2006-03-31 2019-12-18 Massachusetts Institute Of Technology System zur gezielten verabreichung von heilmitteln
CA2652280C (en) 2006-05-15 2014-01-28 Massachusetts Institute Of Technology Polymers for functional particles
US9381477B2 (en) 2006-06-23 2016-07-05 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
AU2007284656A1 (en) * 2006-08-14 2008-02-21 Thymon, L.L.C. Compositions and methods for the treatment and prophylaxis of multiple strains and subtypes of HIV-1
WO2008098165A2 (en) 2007-02-09 2008-08-14 Massachusetts Institute Of Technology Oscillating cell culture bioreactor
JP2010523595A (ja) 2007-04-04 2010-07-15 マサチューセッツ インスティテュート オブ テクノロジー ポリ（アミノ酸）ターゲッティング部分
EP3424525A1 (de) 2007-10-12 2019-01-09 Massachusetts Institute Of Technology Impfstoffnanotechnologie
GB0802224D0 (en) 2008-02-06 2008-03-12 Inst Superiore Di Sanito Process for the production of vaccine components
ES2648196T3 (es) 2008-02-07 2017-12-29 The University Of Washington Dispositivo aerosol circunferencial
EP2106803A1 (de) * 2008-04-04 2009-10-07 Fondazione Centro San Raffaele del Monte Tabor Verfahren zum Entwurf von sich überlappenden Peptiden und Verwendungen der Peptide zur Messung von T-Zell Antworten in HIV Patienten
WO2009139004A2 (en) * 2008-05-14 2009-11-19 Jawaharlal Nehru Centre For Advanced Scientific Research Tat dna sequences, gene constructs, vaccine and processes thereof
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US8530431B2 (en) 2009-03-23 2013-09-10 Pin Pharma, Inc. Treatment of cancers with immunostimulatory HIV TAT derivative polypeptides
CA2790426A1 (en) * 2010-02-18 2011-08-25 Emory University Vectors expressing hiv antigens and gm-csf and related methods for generating an immune response
US20110287045A1 (en) * 2010-05-20 2011-11-24 Zongdong Li Enhanced immune response against infections
EP4088769A1 (de) 2011-03-03 2022-11-16 Impel Pharmaceuticals Inc. Vorrichtung für nasale arzneimittelabgabe
JP6645735B2 (ja) 2011-05-09 2020-02-14 インペル ニューロファーマ インコーポレイテッド 鼻薬送達用ノズル
RU2670488C2 (ru) * 2012-09-13 2018-10-23 Юниверсите Де Женев Новые проникающие в клетку пептиды
CN103880961A (zh) * 2012-12-19 2014-06-25 邱书奇 一种诱导免疫耐受融合肽构建
CA2909954C (en) 2013-04-28 2021-03-23 Impel Neuropharma, Inc. Medical unit dose container
AU2014329393B2 (en) 2013-10-04 2020-04-30 Pin Pharma, Inc. Immunostimulatory HIV Tat derivative polypeptides for use in cancer treatment
ES2804750T3 (es) 2014-04-24 2021-02-09 Janssen Sciences Ireland Unlimited Co Uso de una proteína accesoria derivada del VIH para la reactivación del VIH latente
MA42708A (fr) 2015-09-10 2018-07-04 Impel Neuropharma Inc Dispositif d'administration nasale en ligne
ES2944314T3 (es) 2016-01-08 2023-06-20 Geovax Inc Composiciones y procedimientos para generar una respuesta inmunitaria frente a un antígeno asociado a un tumor
CN105535937B (zh) * 2016-03-11 2018-03-13 刘红 一种用于治疗类风湿性关节炎的皮下注射用原位凝胶
EP3512537B1 (de) * 2016-09-15 2023-11-01 Elicera Therapeutics AB T-zell-immuntherapie
US11311612B2 (en) 2017-09-19 2022-04-26 Geovax, Inc. Compositions and methods for generating an immune response to treat or prevent malaria
KR102131898B1 (ko) * 2017-10-31 2020-07-08 주식회사 노벨티노빌리티 Scf 및 갈렉틴-1을 표적으로 하는 이중표적항체 및 그 용도
CA3081680A1 (en) 2017-11-21 2019-05-31 Impel Neuropharma, Inc. Intranasal device with inlet interface
EP3713628A4 (de) 2017-11-21 2021-08-18 Impel Neuropharma Inc. Intranasale vorrichtung mit tauchrohr
KR20200118032A (ko) 2018-01-05 2020-10-14 임펠 뉴로파마 인코포레이티드 정밀 후각기관 장치에 의한 디하이드로에르고타민의 비강내 전달
AU2019205329B2 (en) 2018-01-05 2023-04-20 Impel Pharmaceuticals Inc. Intranasal delivery of olanzapine by precision olfactory device
WO2020018959A1 (en) 2018-07-19 2020-01-23 Impel Neuropharma, Inc. Respiratory tract delivery of levodopa and dopa decarboxylase inhibitor for treatment of parkinson's disease
CN113473967B (zh) 2019-01-03 2022-09-09 英倍尔制药公司 经鼻药物递送装置
CN113287013B (zh) * 2019-01-04 2025-04-15 国立大学法人京都大学 溃疡性大肠炎以及原发性硬化性胆管炎的检查方法
KR20220010011A (ko) 2019-05-17 2022-01-25 임펠 뉴로파마 인코포레이티드 일회용 비강 전달 장치
JP7602457B2 (ja) 2019-06-06 2024-12-18 デンカ株式会社 ペプチド核酸を基盤としたアジュバント
KR20220121867A (ko) * 2019-12-31 2022-09-01 시아먼 유니버시티 분자의 세포 내 전달을 위한 다량체화 전달 시스템
CN111450082A (zh) * 2020-04-26 2020-07-28 天津大学 一种系统性红斑狼疮治疗纳米颗粒的合成方法
CN115869416A (zh) * 2021-09-28 2023-03-31 上海交通大学医学院附属第九人民医院 用于眼部靶向递药的细胞膜、药物载体、组合物及其制备方法和用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9720585D0 (en) * 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine
IT1297090B1 (it) * 1997-12-01 1999-08-03 Barbara Ensoli Tat di hiv-1 o suoi derivati, da soli od in combinazione, a scopo vaccinale, profilattico e terapeutico, contro l'aids i tumori e le
FI105105B (fi) * 1998-02-27 2000-06-15 Finnish Immunotechnology Ltd O Itsereplikoiva DNA-vektori immunisoimiseksi HIV:ta vastaan
WO2000078969A1 (en) * 1999-06-21 2000-12-28 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv tat peptides and multiple peptide conjugate system
AU5821000A (en) 1999-06-29 2001-01-31 Smithkline Beecham Biologicals (Sa) Vaccine
DE60044303D1 (de) 1999-08-12 2010-06-10 Inist Inc Nicht-immunsuppresives hiv tat-protein
US6485977B1 (en) * 1999-09-13 2002-11-26 Cornell Research Foundation, Inc. Recombinant constructs and techniques for delivering to eucaryotic cells bacterial proteins that are secreted via type III secretion systems
WO2001054717A1 (en) 2000-01-31 2001-08-02 Vic Jira Vaccine composition, process and methods
WO2001054719A2 (en) 2000-01-31 2001-08-02 Smithkline Beecham Biologicals S.A. Vaccine for the prophylactic or therapeutic immunization against hiv
US6544780B1 (en) 2000-06-02 2003-04-08 Genphar, Inc. Adenovirus vector with multiple expression cassettes
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung

Also Published As

Publication number Publication date
DK1425035T3 (da) 2011-08-29
EA200400227A1 (ru) 2004-06-24
US7811573B2 (en) 2010-10-12
CN1318091C (zh) 2007-05-30
EP1425035A1 (de) 2004-06-09
CA2455227C (en) 2012-01-24
JP2005505520A (ja) 2005-02-24
ES2367255T3 (es) 2011-10-31
EA006850B1 (ru) 2006-04-28
CN1533284A (zh) 2004-09-29
HUP0400660A2 (hu) 2005-01-28
JP5134183B2 (ja) 2013-01-30
NZ531364A (en) 2005-12-23
WO2003009867A1 (en) 2003-02-06
AP2004002986A0 (en) 2004-03-31
BR0211474A (pt) 2004-07-13
PL368243A1 (en) 2005-03-21
EP1425035B1 (de) 2011-05-25
IL160015A0 (en) 2004-06-20
OA12701A (en) 2006-06-23
EP1279404A1 (de) 2003-01-29
US20050036985A1 (en) 2005-02-17
MXPA04000287A (es) 2005-03-07
CA2455227A1 (en) 2003-02-06
AU2002331350B2 (en) 2008-06-12

Similar Documents

Publication Publication Date Title
ATE510558T1 (de) Verwendung von biologisch aktivem hiv-1 tat, fragmenten oder derivaten davon, zur bestimmung und/oder aktivierung von antigen-präsentierenden zellen, und/oder zur abgabe von cargo-molekülen für impfung und/oder für behandlung von anderen erkrankungen
CY1119951T1 (el) Συνθεσεις για αυξηση δραστηριοτητας τελομερασης και αγωγη λοιμωξης hiv
ATE518841T1 (de) Herstellung und verwendung von arylalkylsäurederivaten zur behandlung von obesitas
DE60023128D1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
ATE489957T1 (de) Mittel zur behandlung von entzündlichen erkrankungen
DE60327622D1 (de) Kombinierte antitachykardie - schrittmacher und hochspannungstherapie zur behandlung von ventrikulären arrhythmien
WO2007024899A3 (en) Use of glp-1, glp-1 derivatives or glp-1 fragments for skin regeneration, stimulation of hair growth, or treatment of diabetes
ATE413178T1 (de) 2-phenoxy- und 2-phenylsulfanyl-benzenesulfonamid derivate mit ccr3 antagonistischer aktivität zur behandlung von asthma und anderen entzündlichen oder immunologischen erkrankungen
ATE429922T1 (de) Topische gel-abgabesysteme zur behandlung von hauterkrankungen
ATE389649T1 (de) Substituierte amin-derivate und deren verwendung zur behandlung von angionese-bedingten erkrankungen
WO2005079822A3 (en) Pharmaceutical composition comprising a fibrin matrix and dermal fibroblasts for the treatment of wounds
DE60230869D1 (de) 4-(phenylpiperazinylmethyl) benzamidderivate und deren verwendung zur behandlung von schmerzen, angst oder gastrointestinalen störungen
ATE415962T1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
ATE344262T1 (de) 2-heteroarylcarbonsäureamide
WO2003039591A3 (de) Allogene vakzine enthaltend eine ein costimulatorisches polypeptid exprimierende tumorzelle
TR200100637T2 (tr) Yeni doğal ürün türevleri
DE60314003D1 (de) 4-(phenylpiperazinylmethyl)benzamidderivate und deren verwendung zur behandlung von schmerzen oder gastrointestinalen erkrankungen
DE60224004D1 (de) Verwendung von il-18 hemmern zur behandlung und/oder prävention von herzkrankheiten
DE60213234D1 (de) 4-(penylpiperidin-4-ylidenmethyl)benzamidderivate und deren verwendung zur behandlung von schmerzen, angstzuständen oder erkrankungen des magen-darm-trakts
ATE291586T1 (de) Humanes antibiotisches protein
WO2002070741A3 (en) Methods, systems and computer program products for determining the biological effect and/or activity of drugs, chemical substances and/or pharmaceutical compositions based on their effect on the methylation status of the dna
DE60202684D1 (de) Pflanzenpräparat zur behandlung und heilung von bronchialen respiratorischen schwierigkeiten
ATE491442T1 (de) 1-phenyl-2- dimethylaminomethylcyclohexanverbindungen zur therapie von depressiven symptomatiken, schmerz und inkontinenz
DE19681032D2 (de) Gentherapeutisches Nukleinsäurekonstrukt, seine Herstellung und Verwendung zur Behandlung von Herzerkrankungen
EP1330271A4 (de) Verwendung von transkriptionsfaktoren zur behandlung von entzündungen und anderen erkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties